首页> 美国卫生研究院文献>Journal of Otology >Histone deacetylases in hearing loss: Current perspectives for therapy
【2h】

Histone deacetylases in hearing loss: Current perspectives for therapy

机译:组蛋白脱乙酰酶在听力损失中的治疗现状

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hearing loss is one of the most frequent health issues in industrialized countries. The pathogenesis and molecular mechanisms of hearing loss are still unclear. Histone deacetylases (HDACs) are emerging as key enzymes in many physiological processes, including chromatin remodeling, regulation of transcription, DNA repair, metabolism, genome stability and protein secretion. Recent studies indicated that HDACs are associated with the development and progression of hearing loss. Dysfunction of HDACs could promote the oxidative stress and aging in the inner ear. In light of considering the current stagnation in the development of therapeutic options, the need for new strategies in the treatment of hearing loss has never been so pressing. In this review, we will summarize the reported literatures for HDACs in hearing loss and discuss how HDAC family members show different performances for the possibility of process of diseases development. The possibility of pharmacological intervention on hearing loss opens a novel path in the treatment of hearing loss.
机译:听力损失是工业化国家中最常见的健康问题之一。听力损失的发病机制和分子机制仍不清楚。组蛋白脱乙酰基酶(HDAC)在许多生理过程中都已成为关键酶,包括染色质重塑,转录调节,DNA修复,代谢,基因组稳定性和蛋白质分泌。最近的研究表明,HDAC与听力损失的发生和发展有关。 HDAC的功能障碍可能会促进内耳的氧化应激和衰老。考虑到当前在治疗选择发展中的停滞,对治疗听力损失的新策略的需求从未如此迫切。在这篇综述中,我们将总结有关HDAC听力损失的文献报道,并讨论HDAC家庭成员如何针对疾病发展过程的可能表现出不同的表现。对听力损失进行药理干预的可能性为听力损失的治疗开辟了一条新途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号